Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

/p>

3 months to September 9 months to September 30, 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Capital expenditure (1) (40.9) (53.5) (135.9) (139.7) Non GAAP free cash flow 137.8 88.5 528.3 472.3

(1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

Non GAAP net debt comprises:

September 30, December 31, 2011 2010 $M $M Cash and cash equivalents 276.4 550.6 Restricted cash 21.0 26.8 Convertible bonds (1,100.0) (1,100.0) Building finance obligation (8.3) (8.4) Non GAAP net debt (810.9) (531.0)

NOTES TO EDITORS

THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... On Thursday, September 11, 2014, the NASDAQ Composite ... finished the day 0.12% lower at 17,049.00, and the S&P ... based as seven out of ten sectors ended the session ... the day at 741.83, down 0.33%, while the index has ... coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
(Date:9/11/2014)... one atom thick sheet of carbon, can be randomly ... of graphene that could have a significant impact on ... it could provide an ultra-strong, non-corrosive coating for a ... solutions can be used to paint various surfaces ranging ... a simple chemical treatment, the resulting coatings behave like ...
Breaking Biology Technology:Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... (OTCBB:IAGX) announced today it has appointed Bill Toomey to ... the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer ... join our board and bring to us his extensive ... benefit greatly from his past experiences and high level ...
... BELL, Pa., June 30, 2011 Inovio Pharmaceuticals, Inc. ... the development of therapeutic and preventive vaccines against cancers ... compelling immune responses in a study of its multi-subtype ... proprietary vaccine delivery technology in sheep, the second large ...
... ORLEANS, June 29, 2011 Ochsner Health System has signed ... e ICU Program to enhance critical care -- a program ... of stay and save lives. As the only healthcare provider ... Ochsner will serve as a statewide resource to community and ...
Cached Biology Technology:Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 3Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 4Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 5Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 6Ochsner Health System will Offer First eICU Program in Louisiana 2Ochsner Health System will Offer First eICU Program in Louisiana 3
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... is no published account where hippopotamuses are demonstrably shown ... of water. But if they can,t swim, how did ... widely accepted models for the methods, patterns, and timing ... Cyprus, Crete, and Madagascar) may need to be reconsidered. ... the mainland are not currently supported by positive ...
(Date:9/15/2014)... the proteins in our cells cooperate with one another. ... of thousands of different proteins find the correct dancing ... body, brain and nervous system. A recent breakthrough at ... down the door and provided a look at the ... Professor emeritus Jens Jrgen Led of the University of ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Protein courtship revealed through chemist's lens 2Protein courtship revealed through chemist's lens 3
... at the second European Lung Cancer Conference shows ... small-cell lung cancer benefit in terms of overall ... Patients treated with hyperfractionated or accelerated radiotherapy ... over a shorter period of time. The benefit ...
... radiotherapy using real-time X-ray images has allowed French doctors to ... liver cancers while minimizing harm to nearby healthy tissue, researchers ... this study we show that it is possible and very ... at any time before or during treatment in terms of ...
... In this latest image acquired by ESA,s Envisat on Thursday ... Gulf of Mexico can be seen as a dark blue ... the oil spill five times larger than first estimated ... coast, threatening environmental disaster. , As efforts are being made ...
Cached Biology News:Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer 2Oil spill in the Gulf of Mexico nears the coast 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Biology Products: